Fig. 19From: Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infectionsA Yomesan in pH 9.34 TBSS: Development of new needle growth vs time under static conditions (0–60 min). B Needle growth from Yomesan-niclosamide in pH 9.34 Tris-buffered saline: length (mm) vs time after addition of TBSS (min)Back to article page